Research
Alzheimer's Test Results Delivered Digitally Didn't Increase Distress
The Brief
- A randomized trial called eSMARTER compared delivering Alzheimer's genetic and biomarker results digitally with delivering them during a telehealth appointment.
- Digital delivery was found to be noninferior to telehealth delivery, meaning it did not increase distress.
- The reported finding comes from MedPage Today coverage of the trial, with results measured one to seven days after APOE results were delivered.
Why it matters
The finding suggests that digital delivery of sensitive Alzheimer's genetic and biomarker results may be a viable alternative to live telehealth consultations without adding psychological distress for patients.
Who’s affected
- clinicians who deliver Alzheimer's genetic and biomarker results
- patients receiving APOE and biomarker testing
- researchers and health systems designing digital results-delivery tools
(MedPage Today) -- Getting Alzheimer's genetic and biomarker results through a digital tool was noninferior to receiving the information during a telehealth appointment, the randomized eSMARTER trial showed. One to 7 days after APOE results were...